Business
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16 New data demonstrate that RAP-219 has a half-life of approximately 22 days RAP-219 was generally well tolerated throughout treatment and follow-up periods BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“R
About this update from Rapport Therapeutics, Inc.
[{"type":"image","alt":"Rapport Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Rapport Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":153,"url":"https://media.zenfs.com/en/globenewswire.com/398dec8a80e8c3a1c183590a167a19e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bJEA9v0oN3uart2zzjf72Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNA--/https://media.zenfs.com/en/globenewswire.com/398dec8a80e8c3a1c183590a167a19e7","width":300,"height":153}},"lazy":false},{"type":"text","content":"Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16","length":242,"tagName":"p"},{"type":"text","content":"New data demonstrate that RAP-219 has a half-life of approximately 22 days","length":74,"tagName":"p"},{"type":"text","content":"RAP-219 was generally well tolerated throughout treatment and follow-up periods","length":79,"tagName":"p"},{"type":"text","content":"BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures (FOS) in a late-breaker podium presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago.","length":563,"tagName":"p"},{"type":"text","content":"In the Phase 2a trial, patients received RAP-219 for 8 weeks and then entered an 8-week follow-up period after treatment ended to evaluate the effect of RAP-219 on long episodes (LEs) – an objective biomarker of epileptiform activity with >90% median concordance with electrographic seizures in this trial – and clinical seizures. Due to RAP-219's long half-life, therapeutic levels of RAP-219 were sustained, resulting in continued biomarker and clinical responses in the 8-week follow-up period. In the first four weeks of follow-up (weeks 9-12), RAP-219 showed even greater reductions in LEs and clinical seizures than were observed during the ...